New Trial – Allogeneic Bone Marrow Mesenchymal Stem Cell Injection for Sarcopenia
The phase 1/2 trial plans to enroll 30 participants to assess CG-BM1’s safety and tolerability, with two doses administered one month apart.
Orthopedic
Umbilical Cord Mesenchymal Stem Cell Injections Lower Pain Scores More Than Hyaluronate in 50-Patient Severe Knee Osteoarthritis Trial
Participants received either four stem cell injections two weeks apart or five weekly hyaluronate injections, with outcomes tracked for 12 months.
Stempeutics Nabs US Patent for Osteoarthritis Treatment Combining Bone Marrow Stem Cells and Hyaluronic Acid
The Indian biotech company previously published a Phase 3 RCT comparing its therapy to placebo in 146 KOA patients.
YiPSCELL Nabs $8M for iPSC-Derived Cartilage Regeneration
YiPSCELL's lead candidate delivers three-dimensional cartilage organoids derived from induced pluripotent stem cells through an injection into the joint cavity.
Novadip Secures €10.4M for Pivotal Phase 3 Bone Repair Cell Therapy Trial
The ongoing US and EU study is testing NVD003, an autologous cell-based therapy, in patients with a rare, difficult-to-treat pediatric bone condition.
Capricor Therapeutics to Present Cardiosphere-Derived Cell Therapy Trial and Open-Label Extension Data at World Muscle Society Congress
The analyses track skeletal muscle and heart outcomes through 24 months in 82 of 106 randomized participants, including delayed-start and natural-history comparisons submitted with a regulatory amendment.
Ernexa Therapeutics Reports Positive Preclinical iPSC-Derived Mesenchymal Stem Cell Study, Advances Oncology Strategy
In mice with collagen-induced arthritis, several ERNA-201 candidates lowered disease severity versus untreated controls, while the company shifts near-term spending to ERNA-101’s planned ovarian cancer trial filing.
ZEO ScientifiX to Expand Umbilical-Cord Stem Cell Offerings to Georgia and Tennessee as New Regenerative Medicine Laws Take Effect
The move is aimed at helping providers meet the new states’ rules on sourcing, consent, documentation and safety reporting, which do not replace federal requirements or FDA approval.
Consano Bio’s Platelet-Derived Biologic May Ease Chronic Sciatica, New Study, Advancing RCT
Nonclinical findings showed the investigational therapy reduced inflammation, tissue damage and pain sensitivity while promoting cellular repair, supporting its ongoing Phase 1 trial.
Kangstem Biotech’s Stem Cell for Knee Osteoarthritis Phase 2a Reports Significant Results
The Korean biotech company reported improved pain, joint function, and MRI-based structural measures versus placebo at 24 weeks, with no drug-related serious adverse events.